Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    07-September-2000      
Issue 147 Next Update - 14:00 UTC 08:00 EST    08-September-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya US Navy Begins Another Clinical Trial Of Malaria DNA Vaccine

Navy Using New Delivery System - The Bioject System

P> Bioject Medical Technologies Inc., a leading developer of needle-free drug delivery systems, announced that the US Naval Medical Research Center began a clinical study of a DNA-based malaria vaccine. The DNA-based malaria vaccine is made by Vical Incorporated, and Vical has licensed DNA-based malaria vaccines to Aventis Pasteur.

Testing is being conducted by a team of US Navy Malaria Program investigators led by CAPT Stephen L. Hoffman, M.D. and CAPT Thomas L. Richie, M.D, PhD. The vaccine, designated MuStDO 5, incorporates five genes that are designed to trigger an immune response against the malaria parasite.

In the current trial, the Biojector ® 2000 is being used for all injections of the vaccine. Earlier clinical testing demonstrated safety and immunogenicity of a single-gene vaccine, and indicated that vaccine delivered with the Biojector ® 2000 needle free injection system elicited a strong cellular immune response.

"Successful proof of principle in our earlier trials gave us the confidence to design the current trial," said CAPT Hoffman, Director of the Navy Malaria Program. "We were pleased by the immune response of the vaccine delivered with the Biojector ® 2000 in earlier trials. We plan to continue to evaluate the Biojector for delivery of DNA malaria vaccines."

"Through our research collaborations, Bioject has been focused on the delivery of DNA vaccines for some time," said Jim O'Shea, Bioject's chairman, president and CEO. "By potentially improving the immune response of DNA-based vaccines, our needle-free technology could add value to the efforts of researchers developing ways to combat complex diseases such as malaria."

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.